Acyvir

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acyvir

What is Acyvir?

Acyvir is an antiviral medication specifically designed to interfere with the replication process of certain viruses. It belongs to a class of drugs known as synthetic purine nucleoside analogues. While it is used to manage and control viral outbreaks, it is important to note that Acyvir is not a cure for viral infections; instead, it works to decrease the severity and duration of symptoms by inhibiting the virus's ability to multiply within the body.

Mechanism of Action

The primary function of Acyvir is to target viral DNA synthesis. Once the medication enters a virally infected cell, it undergoes a chemical conversion that allows it to act as a substitute for the natural building blocks of DNA. When the virus attempts to replicate its genetic material, Acyvir integrates into the DNA chain, causing premature termination of the chain's growth. This process significantly slows the spread of the virus, allowing the body's immune system to respond more effectively.

Applications and Use

Acyvir is utilized in the management of several conditions caused by specific members of the herpesvirus family. These typically include:

  • Herpes Simplex Virus (HSV): It is used for both initial and recurrent episodes of mucosal and cutaneous infections, including cold sores and genital herpes.
  • Varicella-Zoster Virus (VZV): It is used to address infections such as shingles (herpes zoster) and chickenpox.

Because the medication is highly selective for infected cells, it has a limited impact on healthy, non-infected human cells. It is available in various formulations, including oral tablets, topical creams, and intravenous solutions, depending on the nature and location of the infection being treated.

What side effects are possible with Acyvir?

Possible side effects and safety information

The safety profile of Acyvir (Aciclovir) is based on adverse reactions classified by government regulatory authorities into defined frequency tiers, reflecting real-world clinical use and post-marketing data. These effects are grouped according to the specific physiological systems involved.

Common reactions, which are officially documented to occur in at least 1 in 100 people, primarily involve the gastrointestinal system and include nausea, vomiting, diarrhea, and abdominal pain. Other common systemic effects reported are headache, dizziness, fatigue, and fever.

Uncommon reactions, which may affect up to 1 in 100 people, are often associated with the skin and subcutaneous tissue disorders, including pruritus (itching), rashes, and urticaria.


Serious Adverse Reactions and Key Constraints

Official labeling lists rare and very rare reactions that are considered clinically significant. Rare reactions, affecting up to 1 in 1,000 people, include serious systemic effects such as anaphylaxis and angioedema. Very rare events, occurring in less than 1 in 10,000 people, include acute renal failure, documented involvement of the hepato-biliary system (hepatitis and jaundice), and reversible neurological reactions (e.g., confusion, hallucinations).

Safety notes for specific populations are included in the regulatory documentation. The frequency of central nervous system effects, such as dizziness and confusion, may be increased in older adults and individuals with renal impairment due to potential changes in systemic drug clearance. A core safety constraint is the requirement to maintain adequate hydration to help reduce the risk of renal toxicity, particularly with systemic administration. The medicine is contraindicated in individuals with known hypersensitivity to Aciclovir or its prodrug, valaciclovir.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose reports for Aciclovir (Acyvir) primarily document toxicity affecting the renal and central nervous systems. Accidental, high-dose oral overdose may result in gastrointestinal symptoms such as nausea and vomiting, along with neurological symptoms including confusion, agitation, or headache.

Documented Severe Outcomes and Required Action

The potential for acute renal failure is the most serious documented physiological outcome, often linked to rapid intravenous administration or pre-existing impaired renal function. Such renal impairment manifests through increases in serum creatinine and blood urea nitrogen. Severe escalation can lead to life-threatening CNS manifestations such as seizures and coma.

Immediate medical attention is required upon the suspicion of overdose or the presentation of severe symptoms. Regulatory documentation states that patients should be observed for signs of toxicity. Management is symptomatic and supportive. Haemodialysis is officially described as a supportive measure that can significantly accelerate the removal of Aciclovir from the bloodstream and may be considered in cases of symptomatic overdose. There is no specific pharmacological antidote documented in the official labeling.

Therapeutic Uses of Acyvir

What Acyvir Treats: Main Uses and Benefits

Acyvir is commonly used in situations involving certain distressing symptoms caused by the herpesvirus family, specifically Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV). It is applied across domains where additional symptomatic support is needed.

The medication is relevant in conditions characterized by periods of heightened symptoms and is commonly used across conditions presenting with acute episodes like genital herpes, shingles, and chickenpox. It helps address symptom clusters that may become intense or disruptive, such as localized pain, burning, itching, and the eruption of blisters and sores.

Acyvir is relevant in conditions characterized by periods of heightened symptoms and may assist with managing recurrent or episodic manifestations. Applied as a continuous strategy (suppressive management), it can help reduce the frequency and/or severity of future flare-ups. This may help maintain a sense of stability when symptoms are more noticeable and supports patients during episodes of heightened discomfort. The medication is applied in clinical settings that involve acute or unstable symptom patterns, such as severe, widespread infections in immunocompromised patients or critical presentations like Herpes Zoster Ophthalmicus. Used in scenarios where additional management of discomfort is required, it assists with maintaining functional stability.

“Acyvir is relevant for easing challenging symptoms associated with the acute phase of viral skin eruptions.”

Quick Fact: Supports Management of Localized Pain and Burning

Eligibility and Restrictions for Use

Who Can and Cannot Use Acyvir? Official Regulatory Information

The eligibility for Acyvir (aciclovir) is defined by regulatory authorities based on specific patient populations and existing medical conditions. Use of the medicine is contraindicated for patients with a known hypersensitivity to the active ingredient aciclovir, its related pro-drug valaciclovir, or any of the formulation's excipients.

Population Restrictions and Eligibility

The regulatory label establishes several conditions for restricted use:

  • Renal Impairment: The dose must be reduced in patients with impaired kidney function, as the drug is primarily cleared through the kidneys. Elderly patients are classified as a restricted group, also requiring consideration for dose reduction due to the likelihood of reduced renal function.
  • Age Groups: Acyvir is generally suitable for adults and children two years and older. Infants and neonates may be eligible for intravenous administration for severe infections.
  • Pregnancy and Lactation: Use during pregnancy is conditional; it should only be considered when regulatory assessment confirms the potential benefits outweigh any unknown risks. Caution is also required during lactation as the drug passes into breast milk.
  • Comorbidities: Caution is advised during administration to populations with underlying neurological abnormalities, severe hepatic or electrolyte abnormalities, and significant hypoxia.

What should I know about interactions with other medicines?

The officially documented interactions for Aciclovir are primarily pharmacokinetic, centering on the drug’s elimination from the body. Aciclovir is largely cleared via active renal tubular secretion, which is the basis for several specific drug-drug interactions. Co-administration of medicines that inhibit this clearance process can increase the systemic exposure of Aciclovir.

Specific examples include Probenecid and Cimetidine. When combined, these substances have been formally documented to increase the Aciclovir plasma Area Under the Curve (AUC) and reduce its renal clearance. Similarly, the simultaneous use of Aciclovir with Mycophenolate Mofetil (MMF) results in increased plasma concentrations for both Aciclovir and the active MMF metabolite, reflecting competitive renal transport.

A key regulatory caution involves the co-administration of Aciclovir with other potentially nephrotoxic drugs, as this combination may heighten the risk of renal dysfunction. This risk is noted to be particularly relevant for elderly patients and individuals with impaired renal function, who already exhibit reduced Aciclovir clearance. Regarding non-medicinal products, the absorption of oral Aciclovir is not significantly affected by food, and regulatory labels do not specify formal restrictions concerning meals.

Mechanism of Action

Selective Activation by Viral Enzymes

The mechanism of Acyvir is anchored in its selective activation, which only occurs within a virus-infected cell. The inactive drug must be recognized by the Viral Thymidine Kinase (vTK), an enzyme produced by the target virus (HSV/VZV), which performs the critical first step of converting it into an active monophosphate. This reliance on a viral enzyme ensures that the drug is mainly activated at the site of infection, conferring a high degree of target selectivity compared to host cell processes.

Termination of Viral DNA Synthesis

Once fully activated to Aciclovir Triphosphate (ACV-TP) by host enzymes, the molecule targets the Viral DNA Polymerase. It acts as a deceptive nucleotide analog, getting incorporated into the growing viral DNA chain. Because it lacks the necessary 3^prime-OH binding site, its incorporation results in obligate DNA chain termination, immediately halting the replication process. This inhibitory cascade results in a virostatic effect, suppressing the virus's ability to multiply and spread.

Mechanism Limitations: Latency

A functional boundary of this mechanism is its non-applicability to the latent virus. Since Viral Thymidine Kinase is only produced during active viral replication, the drug cannot be activated when the virus is in its latent phase within the nerve ganglia. The mechanism's dependence on an actively replicating pathogen means the drug's activity is constrained; it does not eliminate the latent viral genome.

Dosage and Administration Information

Acyvir (Aciclovir) is administered according to specific, documented protocols that define the route, dose, and frequency of use.

Administration Scope

The medicine is available for administration via Oral (tablet, capsule, suspension), Intravenous (IV) Infusion, Topical (cream, ophthalmic ointment), and Buccal routes. Oral dosing typically ranges from 200 mg to 800 mg per dose, with a frequency varying from twice daily for suppressive management to five times daily for treating acute infections, such as Herpes Zoster. The oral forms may be taken with or without food. Administration to older adults should consider a potential need for dose adjustment due to likely reduced renal clearance.

Procedural Requirements

Specific preparation and administration steps are defined for certain forms. The IV solution requires reconstitution and subsequent dilution to a low concentration (not exceeding 7 mg/mL) prior to infusion. IV administration must be delivered slowly over at least one hour and is strictly prohibited from being administered via the intramuscular or subcutaneous routes. Procedural adjustments are required for patients with reduced renal function, where the dose or dosing interval is modified based on creatinine clearance. Acute treatment courses are time-limited, generally 5 to 10 days, while suppressive therapy is typically re-evaluated after 12 months. Adequate hydration should be maintained during IV therapy. If a dose is missed, the standard approach is to take it as soon as possible, unless the next scheduled dose is nearly due, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acyvir (Aciclovir)

The research landscape for Acyvir is primarily defined by clinical studies that examined outcomes in conditions characterized by fluctuating or episodic manifestations caused by the Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV). The available evidence contributes to understanding the short-term symptom patterns in the observed populations.


Evidence Overview for Herpes Simplex Virus (HSV) Infections

Research for Managing Acute Episodes (Initial and Recurrent)

Clinical research for acute herpes episodes primarily consists of short-term Randomized Controlled Trials (RCTs). These studies were applied in studies examining patient-reported experiences and focused on two main outcomes related to physical discomfort: the time required for lesions to heal, crust over, or resolve, and the duration of localized pain. The findings describe patterns observed in the studies related to the time taken for symptoms to resolve or change. This research provides insight into short-term changes, but the follow-up durations were limited in many of these trials.

Research for Suppressive Management

When Acyvir was studied for continuous daily use, the trials tended to be longer, often lasting six to twelve months. Research explored outcomes describing episodic or acute changes, specifically tracking the frequency of recurrence episodes over time. The data show patterns related to the frequency of recurrence episodes during the period of observation.


Evidence Overview for Varicella Zoster Virus (VZV) Infections

The evidence for VZV infections was examined in trials focusing on conditions associated with acute or disruptive episodes, particularly shingles (Herpes Zoster).

Research Focus on Herpes Zoster (Shingles) Outcomes

The evidence for shingles is supported by RCTs that tracked outcomes linked to inflammatory or irritative states. Studies explored patient-reported outcomes describing perceived discomfort related to post-herpetic neuralgia (PHN). The research generally describes that outcomes were studied in relation to when treatment was initiated, specifically within the first three days (72 hours) of the rash appearing.

Research Focus on Varicella (Chickenpox) in Pediatric Populations

Research related to chickenpox primarily uses RCTs involving specific groups of children. These studies monitored outcomes monitoring physiological strain or stress, such as the duration of fever and the time until new lesion formation ceased.

Key Studies & References

  1. Acyclovir - StatPearls - NCBI Bookshelf - NIH (Comprehensive drug monograph)
  2. Herpes Zoster Ophthalmicus - StatPearls - NCBI Bookshelf (Guideline for complex VZV infection)

Frequently Asked Questions (FAQ)

Common questions about Acyvir (FAQ)

Q: How quickly does Acyvir usually start working?

A: According to official product information, Acyvir is rapidly absorbed after oral administration and typically reaches its highest concentration in the bloodstream within a few hours. The drug's antiviral action is selective and begins once it is activated by the virus inside the infected cells, which then contributes to the drug's virostatic effect.

Q: Does Acyvir stay in your system for a long time?

A: Studies on how the medicine moves through the body indicate that the mean half-life for Acyvir is approximately 2.5 to 3 hours. This figure is used to describe the drug’s elimination rate from the body. Acyvir is primarily cleared from the body through the kidneys, mostly in its unchanged form.

Q: What happens if a dose of Acyvir is missed?

A: Official administration instructions advise taking a missed dose as soon as it is remembered. However, if the time for the next scheduled dose is nearly due, regulatory information recommends skipping the missed dose and continuing with the regular schedule. Official instructions do not advise doubling the next scheduled dose.

Q: Can Acyvir cause tiredness or fatigue?

A: Yes, official regulatory documents list both fatigue and headache as common reactions associated with Acyvir. Common means these effects are reported to occur in at least 1 in 100 people during use. Tiredness is a related systemic effect that patients often report alongside fatigue.

Q: Can Acyvir cause stomach upset or nausea?

A: Gastrointestinal reactions are commonly reported when using Acyvir. Official safety data lists nausea, vomiting, diarrhea, and abdominal pain as common side effects, meaning they are experienced by at least 1 in 100 people.

Q: Does taking Acyvir require any special diet restrictions?

A: Official labels state that the drug's absorption is not significantly affected by taking it with food, and no formal restrictions concerning meals or specific diets are specified. However, adequate hydration is noted in regulatory information, particularly with IV administration.

Q: Can Acyvir cause dizziness?

A: Dizziness is documented in official safety sources as a common adverse reaction, meaning it has been reported in at least 1 in 100 people using the medicine.

Q: Does Acyvir have a known effect on mental clarity?

A: Official labeling notes that neurological reactions such as confusion, agitation, or somnolence (drowsiness) are reported, though these are listed as very rare events. Official safety notes advise that effects may require consideration in older adults or individuals with existing kidney impairment.

Q: Is Acyvir used differently in children compared to adults?

A: Acyvir is generally suitable for adults and children two years and older. The approach for children differs primarily in that dosage adjustments are based on body weight. Intravenous administration may also be used for infants and neonates in cases of severe infections.

Q: Is Acyvir known to interact with common pain relievers?

A: General regulatory caution is advised regarding co-administration with other potentially nephrotoxic drugs, as Acyvir is cleared via the renal system. Specific common pain relievers may not be listed in all regulatory summaries, but any medicine that affects the kidneys requires consideration.

Q: Is Acyvir used for conditions other than those listed in the official documents?

A: Official documents define the approved uses for Acyvir, such as the management of initial and recurrent herpes simplex virus (HSV) infections. While clinical reference sources may note other uses, these are not formally approved indications by regulators.

Q: Is it generally acceptable to drink alcohol while using Acyvir?

A: Official regulatory labels typically do not prohibit alcohol consumption. However, public health guidance based on regulatory data often advises awareness of potential side effects, as alcohol may contribute to the occurrence or severity of common reactions like headaches or dizziness.

Q: Does Acyvir change how birth control pills work?

A: Official regulatory data reports no known direct interaction between Acyvir and oral contraceptives. However, common side effects such as severe vomiting or diarrhea, if they occur, may impact the absorption of any concurrently administered medicine.

Q: Can Acyvir interact with cold and flu medications?

A: Interactions are determined by the specific components within the cold or flu medication. Regulatory sources advise considering any co-administered medicine that might affect kidney function, as Acyvir is cleared through the kidneys.

Q: Does Acyvir affect the liver?

A: Official safety data lists very rare effects on the liver and biliary system, including reports of elevated liver function tests, hepatitis, and jaundice. Because of this, official documents advise caution for populations with serious hepatic abnormalities.

Q: Can Acyvir interact with herbal supplements?

A: Regulatory guidance notes that limited information is typically available regarding interactions with herbal products, as they are often not tested in the same manner as prescription medicines. It is generally challenging to confirm the interaction profile for all herbal products.

Q: Is Acyvir available as a cream or only as a pill?

A: Acyvir is available in multiple forms to allow for different routes of administration. These include oral tablets, capsules, and suspension, as well as topical cream, ophthalmic ointment, and intravenous solutions.

Q: How long do people usually take Acyvir?

A: The duration of use depends heavily on the condition being addressed. Acute treatment courses are often time-limited to 5 to 10 days. Suppressive therapy, used to prevent recurrent episodes, may last for 12 months or longer but is subject to professional re-evaluation.

Q: What happens if Acyvir is taken for too long?

A: Acute treatment courses are time-limited, and long-term systemic use is generally restricted to conditions requiring suppressive therapy, which is subject to professional re-evaluation. Prolonged or excessive use beyond the prescribed limits may increase the risk of adverse reactions, particularly potential effects on the kidneys and nervous system.

Q: Does Acyvir interact with vitamin supplements?

A: Specific regulatory guidance for general vitamin supplements is limited, and most do not have known direct interactions. However, a few individual high-dose vitamins may have specific safety notes, especially for individuals who may be susceptible to kidney stones, as Acyvir can affect the renal system.

Q: Can Acyvir be crushed or split?

A: The official label notes that Acyvir tablets and capsules are designed for oral ingestion. While a liquid suspension is available for those with swallowing difficulties, altering the standard oral forms can potentially affect the drug’s absorption, which may lead to variability in the amount of medicine the body receives.

Q: Are there any known interactions between Acyvir and vaccines?

A: Yes, Acyvir is documented to interact with the live, attenuated varicella virus vaccine, which is used for chickenpox and shingles. Concomitant use may result in a diminished immune response, and the antiviral is typically avoided for a specific period of time both before and after receiving this type of vaccine.

Q: Why is Acyvir often prescribed for initial outbreaks?

A: Clinical research has examined that starting treatment early, typically within a few days of symptom onset, relates to outcomes describing a potentially shorter duration of acute infection and faster resolution of physical symptoms. This evidence supports its established use for initial outbreaks.

How should Acyvir be stored and disposed of?

How to Store and Dispose of Acyvir (Aciclovir)

Official regulatory documents define strict conditions for storing and disposing of Acyvir to maintain its quality.


Storage Requirements

Acyvir tablets and capsules must be stored at Controlled Room Temperature, between 20°C and 25°C. Storage requires protection from moisture and light, and the dispensed container must be kept tightly closed.

  • Oral Suspension: The liquid formulation is explicitly mandated not to be frozen or refrigerated and must be stored below 25°C.
  • Child Safety: All forms of the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Acyvir must be handled as pharmaceutical waste. Official instructions state the product should not be disposed of via wastewater or regular household waste. Disposal must occur in accordance with local requirements, often by returning the medicine to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acyvir found in:

A-Z Index: